Wen-Jun Wu

Wen-Jun Wu


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2010 in Cancer Science
Verified
Journal Article
Open access
PDF file
JYJaw‐Ji Yang
Jaw‐Ji Yang
YLYi‐Ju Lee
Yi‐Ju Lee
HHHsin‐Hung Hung
Hsin‐Hung Hung
WTWei‐Pu Tseng
Wei‐Pu Tseng
CTChuan‐Chou Tu
Chuan‐Chou Tu
WWWen-Jun Wu
Wen-Jun Wu
Novel mixed‐lineage kinase protein zipper sterile‐α‐motif kinase (ZAK) was first cloned by our laboratory. Lung cancer is the leading cause of cancer‐related death in the world, including in Taiwan. Here, we wanted to investigate whether ZAK plays a potential role in lung cancer development. First, Western blot analysis results demonstrated that four cell lines expressed high levels of ZAK from among a panel of 10 lung cancer cell lines, and two of three normal lung cells expressed ZAK. ZAK gene expressions were down‐regulated in lung cancers by real‐time PCR analysis. Overexpression of ZAK suppressed cell proliferation in parallel with increased phosphorylated levels of extracellular signal‐regulated kinase (ERK) and c‐Jun N‐terminal kinase (JNK). In contrast, ZAK silencing cells inhibited the expressions of phosphorylated ERK and JNK without affecting the expression of phosphorylated p38. The effect of the decreased cell growth rate was significantly but incompletely reversed when ZAK‐overexpressing cells were treated with a specific ERK or JNK inhibitor. Moreover, c‐Fos and c‐Jun, the major downstream components of MAPKs, were up‐regulated by ERK and JNK, respectively. When ZAK‐overexpressing cells introduced with c‐Jun RNA interference (RNAi), the activator protein‐1 (AP‐1) transcription activity detected by a secreted alkaline phosphatase (SEAP) assay was suppressed and the decreased cell number was reversed compared with the control RNAi‐treated group. More importantly, ZAK significantly depressed tumor growth in in vivo study. Taken together, results from both in vitro and in vivo studies indicated that the decrease of lung cancer cell proliferation by ZAK may involve the ERK and JNK pathways via an AP‐1 transcription factor. ( Cancer Sci 2010)

Verified
Journal Article
Open access
PDF file
SHShih-Cheng Huang
Shih-Cheng Huang
SGShuo-Yan Gau
Shuo-Yan Gau
JHJing-Yang Huang
Jing-Yang Huang
WWWen-Jun Wu
Wen-Jun Wu
CHENGCHUNG WEICHENGCHUNG WEI
CHENGCHUNG WEI
Background: Non-T2 asthma and hypothyroidism share several inflammatory mechanisms in common. However, large-scale, real-world studies evaluating the association between asthma and hypothyroidism are lacking. The objective of this study was to evaluate the risk for asthma patients of developing hypothyroidism. Methods: In the retrospective cohort study, people with asthma were recruited from the Longitudinal Health Insurance Database in Taiwan. After excluding ineligible patients with a previous history of hypothyroidism, 1:1 propensity matching was conducted to select a non-asthma control group. Based on the multivariate Cox regression model, the adjusted hazard ratio of asthma patients developing hypothyroidism was calculated. Results: In total, 95,321 asthma patients were selected as the asthma group and the same amount of people without asthma were selected as the control group. The incidence levels of new-onset hypothyroidism in asthma and non-asthma groups were 8.13 and 6.83 per 100,000 people per year, respectively. Compared with the non-asthma group, the adjusted hazard ratio of the asthma group developing hypothyroidism was 1.217 (95% confidence interval, 1.091–1.357). Conclusions: We found having asthma to be associated with an increased risk of hypothyroidism. Clinicians should be concerned regarding the endocrinological and inflammatory interaction between the two diseases while caring for people with asthma.

1 June 2011 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
CCChing-Yuan Cheng
Ching-Yuan Cheng
SCShur-Hueih Cherng
Shur-Hueih Cherng
WWWen-Jun Wu
Wen-Jun Wu
TYTSUNG-YING YANG
TSUNG-YING YANG
XHXin-Yi Huang
Xin-Yi Huang
Gwo-Tarng SheuGwo-Tarng Sheu
Gwo-Tarng Sheu

CLCi-Wen Luo
Ci-Wen Luo
YCYun-Wei Chiang
Yun-Wei Chiang
HSHan-Ying Sun
Han-Ying Sun
KYKun-Lin Yeh
Kun-Lin Yeh
MLMin-Wei Lee
Min-Wei Lee
Yu-Hsiang KuanYu-Hsiang Kuan
Yu-Hsiang Kuan
Patients with NTG or POAG with more than one outpatient or discharge diagnosis from the ophthalmology department were included in the study. These data were merged with the PM2.5 data from the Air Quality Monitoring Network for analysis. This was a case–control study, with 1006 participants in the NTG group and 2533 in the POAG group. To investigate fine particulate matter (PM2.5) exposure levels in patients with normal-tension glaucoma (NTG) and primary open-angle glaucoma (POAG), patient data were obtained from Taiwan’s Longitudinal Health Insurance Database 2000 for the 2008 to 2013 period. We used a multivariate logic regression model to assess the risk for each participant. The PM2.5 exposure levels were divided into four groups: <25th percentile (Q1), 75th percentile (Q4), >2113 μg/mm3. The results are expressed in terms of odds ratio (OR) and 95% CI. A multiple logistic regression was used to compare the results of the NTG group with those of the POAG group. Compared with the PM2.5 Q1 level, the OR of the PM2.5 Q2 level was 1.009 (95% CI 0.812–1.254), the PM2.5 Q3 level was 1.241 (95% CI 1.241–1.537, p < 0.05), and the PM2.5 Q4 level was 1.246 (95% CI 1.008–1.539, p < 0.05). Our research reveals that compared with POAG, the risk of developing NTG is more closely related with PM2.5 exposure, and PM2.5 has a concentration–dose effect. It is hoped that in the future, in the clinical judgment of NTG and POAG, the level of PM2.5 in the environment can be taken as a risk factor.

CLCi-Wen Luo
Ci-Wen Luo
SCShih-Pin Chen
Shih-Pin Chen
CCChen-Yu Chiang
Chen-Yu Chiang
WWWen-Jun Wu
Wen-Jun Wu
CCChun-Jung Chen
Chun-Jung Chen
Yu-Hsiang KuanYu-Hsiang Kuan
Yu-Hsiang Kuan
Depression is a common mental disorder that affects more than 264 million people worldwide. Anxiety, diabetes, Alzheimer’s disease, myocardial infarction, and cancer, among other disorders, are known to increase the risk of depression. Exposure to ultraviolet B (UVB) can cause human serotonin levels to increase. The vitamin D pathway is one mechanism through which ultraviolet light absorbed through the skin can affect mood; however, UVB exposure is known to increase the risk of cancer. In this study, we explored the effects of prolonged exposure to UVB on depression. Data were retrieved from the Taiwan National Health Insurance Research Database for 2008 to 2013. Each patient with depression was matched 1:4 with a comparison patient by sex and age (±5 years); thus, the study included 23,579 patients with depression and 94,316 healthy controls for comparison. The patients had been exposed to UVB for at least 1 year to observe the cumulative effect of UVB exposure. Based on the World Health Organization UV index, we divided the observation period data into five UV levels: low, moderate, high, very high, and extreme. A multivariate Poisson regression model was used to assess the risk of depression according to UVB exposure level, adjusting for sex, age, income, urbanization level, month, and comorbidities. The results revealed that the incidence rate ratio (IRR) for patients with depression was 0.889 for moderate levels (95% CI 0.835–0.947), 1.134 for high levels (95% CI: 1.022–1.260), 1.711 for very high levels (95% CI: 1.505–1.945), and 2.785 for extreme levels (95% CI: 2.439–3.180) when compared to low levels. Moderate levels of UVB lowered the risk of depression, while high levels of UVB gradually increased the risk. We propose that UVB at normal concentrations can effectively improve depression. However, exposure to high concentrations of UVB damage DNA results in physical diseases such as skin cancer, which increase the risk of depression.

9 January 2023 in Frontiers in Medicine
Verified
Journal Article
Open access
SHShih-Cheng Huang
Shih-Cheng Huang
TCTsu-Man Chiu
Tsu-Man Chiu
CLChien-Ying Lee
Chien-Ying Lee
HCHui-Chin Chang
Hui-Chin Chang
WWWen-Jun Wu
Wen-Jun Wu
SGShuo-Yan Gau
Shuo-Yan Gau
Background: In the field of autoimmune and inflammatory disorders, different approaches were applied to provide information regarding disease activity, comorbidities, epidemiological reports and risk factors. However, no previous studies had thoroughly analyzed the research trend in the field, and the bibliometric analysis focusing on pemphigoid diseases was available. The objective of the current study was to evaluate the current research trend in the field.Methods: A search has been conducted for the Web of Science database based on various subcategories of pemphigoid diseases. Detailed information including articles’ publication types, Author information, citation, and publication information was attained for further analysis.Results: Within the 6,995 studies, the top 100 most-cited articles were extracted for analysis. Among the top 100 studies, 70% of the studies focused on bullous pemphigoid. More than 60% of the top 100 studies were studies with original data. Furthermore, 30% of the studies were guidelines and narrative reviews. For the issues primarily focused on, most of the high-impact studies described the molecular mechanism of pemphigoid diseases (26%), managements (19%), risk factors of pemphigoid diseases (17%). Additionally, some other studies provided general review or discussed about the issue of epidemiology, diagnosis/definition, comorbidities and clinical characteristics of pemphigoid diseases.Conclusion: This comprehensive bibliographic study of pemphigoid diseases provided an overview of current research focuses in the field. Topics such as disease management, molecular mechanism of pathogenesis, and drug-inducing pemphigoid diseases were highly mentioned in the most-cited studies. For researchers and clinicians, the researching trend and study focus in the top-100 cited studies could serve as a potential reference for future investigation and patient management.